Molecular and Cellular Biochemistry

, Volume 268, Issue 1–2, pp 19–24 | Cite as

Evaluation of serum lipids and high-density lipoprotein subfractions (HDL2, HDL3) in postmenopausal patients with breast cancer

  • V. Michalaki
  • G. Koutroulis
  • G. Koutroulis
  • K. Syrigos
  • C. Piperi
  • A. Kalofoutis


Breast cancer patients are known to be at increased risk for developing other chronic diseases including cardiovascular disease. Studies by different investigators have shown a correlation between increased dietary fat or hypercholesterolemia and the occurrence of breast cancer. Since previous studies on lipoprotein subfractions in this type of cancer have been inconsistent, we evaluated the lipids and lipoprotein subfraction levels in postmenopausal patients with breast cancer in an attempt to identify the risk for the development of cardiovascular disease.

The study included 132 patients, 56 of which were suffering from breast cancer, 32 from pancreatic and 44 age-matched controls. Total cholesterol (TC), triglycerides and lipoprotein fractions as well as TC/High density lipoprotein (HDL) and HDL2/HDL3 ratios were estimated by standard laboratory techniques.

An increase in triglycerides and a decrease in HDL-cholesterol, especially in the HDL2 subfraction, were observed in patients with breast cancer as compared to the controls (P < 0.05). The maximum changes in TC, and HDL concentrations were observed in patients with advanced disease. Analysis of indexes of atherosclerosis (TC/HDL, and HDL2/HDL3 ratios) demonstrated that breast cancer patients had significantly higher TC/HDL ratio (6.44 ± 1.24) compared with controls (3.43 ± 0.57, p = 0.001), and patients with pancreatic cancer (3.79 ± 0.15, p = 0.027).

The results have demonstrated an unfavourable lipid profile in untreated breast cancer patients with high atherosclerosis indexes. This observation is of great importance, considering the potential use of endocrine therapy that could result in further deterioration of lipid indexes. We propose the evaluation and monitoring of lipid profile prior and after the induction of hormonal therapy in breast cancer patients, as a routine in clinical setting. (Mol Cell Biochem 268: 19–24, 2005)

Key words

lipoproteins ultracentrifugation breast cancer endocrine therapy coronary artery disease 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Feinleib M: A possible inverse relationship between serum cholesterol and cancer mortality. Am J Epidemiol 114: 5–10, 1981Google Scholar
  2. 2.
    Kritchevsky SB, Kritchevsky D: Serum cholesterol and cancer risk: An epidemiologic perspective. Ann Rev Nutr 12: 391–416, 1992Google Scholar
  3. 3.
    Kritz H, Zielinski C, Sinzinger H: Low cholesterol and cancer. J Clin Oncol 11: 3043–3048, 1996Google Scholar
  4. 4.
    Schreier LE, Berg GA, Basilio FM, Lopez GI, Etkin AE, Wikinski RL: Lipoprotein alterations, abdominal fat distribution and breast cancer. Biochem Mol Biol Int 4: 681–690, 1999Google Scholar
  5. 5.
    Clavel-Chapelon F, Niravong M, Joseph RR: Diet and breast cancer: Review of the epidemiologic literature. Cancer Detect Prev 21: 426–440, 1997Google Scholar
  6. 6.
    Moorman PG, Hulka BS, Hiatt RA, Krieger N, Newman B, Vogelman JH, Orentreich N: Association between high-density lipoprotein cholesterol and breast cancer varies by menopausal status. Cancer Epidemiol Biomarkers Prev 6: 483–488, 1998Google Scholar
  7. 7.
    Lane DM, Boatman KK, McConathy WJ: Serum lipids and apolipoproteins in women with breast masses. Breast Cancer Res Treat 34: 161–169, 1995CrossRefGoogle Scholar
  8. 8.
    Mady EA: Association between estradiol, estrogen receptors, total lipids, triglycerides, and cholesterol in patients with benign and malignant breast tumours. Cancer Detect Prev 21: 426–440, 1997Google Scholar
  9. 9.
    Rossner S, Wallgren A: Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 52: 339–246, 1984PubMedGoogle Scholar
  10. 10.
    Elisaf MS, Bairaktari ET, Nicolaides C, Kakaidi B, Tzallas CS, Katsaraki A, Pavlidis NA: Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 37: 1510–1513, 2001CrossRefGoogle Scholar
  11. 11.
    Engan T, Krane J, Johannessen DC, Lonning PE, Kvinnsland S: Plasma changes in breast cancer patients during endocrine therapy – lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Res Treat 36: 287–297, 1995CrossRefGoogle Scholar
  12. 12.
    Assmann G, Schulte H: Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 70: 733–737, 1992Google Scholar
  13. 13.
    Musliner TA, Krauss RM: Lipoprotein subspecies and risk of coronary disease. Clin Chem 34: 78–83, 1988Google Scholar
  14. 14.
    Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62: 707–714, 1977CrossRefPubMedGoogle Scholar
  15. 15.
    Eisenberg S: High density lipoprotein metabolism. J Lipid Res 25: 1017–1058, 1984Google Scholar
  16. 16.
    De Lalla OF, Gofman JW: Ultracentrifugal analysis of serum lipoproteins. Methods Biochem Anal 1: 459–478, 1954Google Scholar
  17. 17.
    Eyre J, Hammett F, Miller NE: A micro-method for the rapid ultracentrifugal separation of human plasma high-density lipoprotein subfractions, HDL2 and HDL3. Clin Chim Acta 114: 225–231, 1998CrossRefGoogle Scholar
  18. 18.
    Allain CC, Poon LS, Chan CS, Richmond W, Fu PC: Enzymatic determination of total serum cholesterol. Clin Chem 20: 470–475, 1974PubMedGoogle Scholar
  19. 19.
    Fossati P, Prencipe L: Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 28: 2077–2080, 1982PubMedGoogle Scholar
  20. 20.
    Goodwin PJ, Boyd NF, Hanna W, Hartwick W, Murray D, Qizilbash A, Redwood S, Hood N, DelGiudice ME, Sidlofsky S, McCready D, Wilkinson R, Mahoney L, Connelly P, Page DL: Elevated levels of plasma triglycerides are associated with histologically defined premenopausal breast cancer risk. Nutr Cancer 27: 284–292, 1997Google Scholar
  21. 21.
    Allampallam K, Dutt D, Nair C, Shetty V: The clinical and biologic significance of abnormal lipid profiles in patients with myelodysplastic syndromes. J Hematother Stem Cell Res 9: 247–255, 2000CrossRefGoogle Scholar
  22. 22.
    Mehta N, Hordines J, Volpe C, Doerr R, Cohen SA: Cellular effects of hypercholesterolemia in modulation of cancer growth and metastasis: A review of the evidence. Surg Oncol 3: 179–185, 1997CrossRefGoogle Scholar
  23. 23.
    Knapp ML, al-Sheibani S, Riches PG: Alterations of serum lipids in breast cancer: Effects of disease activity, treatment, and hormonal factors. Clin Chem 37: 2093–2101, 1991Google Scholar
  24. 24.
    Alexopoulos CG, Blatsios B, Avgerinos A: Serum lipids and lipoprotein disorders in cancer patients. Cancer 60: 3065–3070, 1987PubMedGoogle Scholar
  25. 25.
    Borrelli R, del Sordo G, De Filippo E, Contaldo F, Parisi V, Beneduce G: High serum HDL-cholesterol in pre- and post-menopausal women with breast cancer in southern Italy. Adv Exp Med Biol 348: 149–153, 1993Google Scholar
  26. 26.
    Boyd NF, Connelly P, Lynch H, Knaus M, Michal S, Fili M, Martin LJ, Lockwood G, Tritchler D: Plasma lipids, lipoproteins, and familial breast cancer. Cancer Epidemiol Biomarkers Prev 4: 117–122, 1995Google Scholar
  27. 27.
    Fiorenza AM, Branchi A, Sommariva D: Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int J Clin Lab Res 30: 141–145, 2000CrossRefGoogle Scholar
  28. 28.
    Vitols S, Gahrton G, Bjorkholm M, Peterson C: Hypocholesterolaemia in malignancy due to elevated low-density-lipoprotein-receptor activity in tumour cells: Evidence from studies in patients with leukaemia. Lancet 8465: 1150–1154, 1985CrossRefGoogle Scholar
  29. 29.
    Ray G, Husain SA: Role of lipids, lipoproteins and vitamins in women with breast cancer. Clin Biochem 34: 71–76, 2001Google Scholar
  30. 30.
    Writing Group for the Women’s Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women’s health initiative randomized controlled trial. JAMA 288: 321–333, 2002Google Scholar
  31. 31.
    Goss PE: Risks versus benefits in the clinical application of aromatase inhibitors. Endocr.Relat Cancer 6: 325–332, 1999Google Scholar

Copyright information

© Kluwer Academic Publishers 2005

Authors and Affiliations

  • V. Michalaki
    • 1
    • 2
  • G. Koutroulis
    • 1
  • G. Koutroulis
    • 1
  • K. Syrigos
    • 2
  • C. Piperi
    • 1
  • A. Kalofoutis
    • 1
  1. 1.Department of Biological ChemistryUniversity of Athens, School of MedicineAthensGreece
  2. 2.Oncology Unit, 3rd Department of Medicine, Athens Medical SchoolSotiria General HospitalAthensGreece
  3. 3.Department of Biological ChemistryUniversity of Athens, School of Medicine, GoudiAthensGreece

Personalised recommendations